Sanofi has completed its acquisition of Blueprint Medicines Corporation, which will now operate as an indirect, wholly owned subsidiary of Sanofi. The acquisition enhances Sanofi's portfolio by adding a commercialized medicine for systemic mastocytosis $(SM)$ and a promising pipeline, along with expertise in rare immunological diseases. The subsidiary strengthens Sanofi's position among allergists, dermatologists, and immunologists, aiding in the advancement of its immunology pipeline. Key assets include Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent SM, and elenestinib, a next-generation investigational drug for SM currently in a phase 2/3 study.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118508-en) on July 18, 2025, and is solely responsible for the information contained therein.